Community Practitioners' and Health Visitors' Association

Back to home pageGeneral information about CPHVAMembership information Contact CPHVA staffSearch CPHVA site for general informationHelp on navigating the siteLinks to other useful sitesEnter members' area

Health visiting information
School nursing information District nursing information Practice nursing information Countries-Scotland, Wales and Northern IrelandPublic health information Clinical effectiveness information Courses, grants and reportsCPHVA responses to government and other reportsCPHVA and non-CPHVA eventsPress releases and media relationsCPHVA campaignsSpecial Interest GroupsFrequently asked questionsIndex to site
Amicustheunion

Prescribing Guide
 
The Department of Health has published a guide to supplementary prescribing on its website. The guide outlines the administrative and procedural steps needed to enable nurses to act supplementary prescribers and also provides advice on good practice for supplementary prescribers and their independent prescribing partners.
 
The website also contains new information outlining the requirements for supervised learning in practice for nurses and midwives intending to train as prescribers from the extended formally of medicines or to act as supplementary prescribers.
 
The report ‘Supplementary prescribing: supervision in practice for nurse and midwife prescribers’ and the guide ‘Supplementary prescribing by nurses and pharmacists within the NHS in England. A guide for implementation.’ can both be downloaded from www.doh.gov.uk/supplementaryprescribing
 
NICE guidance on flu
The National Institute for Clinical Excellence (NICE) has recommended that amantadine should not be used for the treatment of flu.
It also says that zanamivir or oseltamivir should not be used to treat a flu-like illness in people who are otherwise healthy (those unlikely to be at risk of developing complications of flu).
 
But when the number of people with flu reaches a high enough level (when influenza virus A or B is circulating in the community) zanamivir or oseltamivir are recommended to treat flu-like illness in people who are considered to be at risk of developing complications, provided they can start treatment within 48 hours of the symptoms starting.
 
NICE has also recommended that monitoring schemes, such as those organised by the Public Health Laboratory Service and the Royal College of General Practitioners, should be used so that the start of an outbreak of influenza can be spotted as quickly as possible.
The guidance can be downloaded from www.nice.org.uk
 
Top